Venoruton 2 % gel Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

venoruton 2 % gel

eg sa-nv - hydroxyéthyl-o-(beta-)-rutoside 2 g/100 g - gel - 2 % - hydroxyéthyl-o-(beta-)-rutoside 20 mg/g - hidrosmin

ADVIL NUIT Capsule Canada - français - Health Canada

advil nuit capsule

glaxosmithkline consumer healthcare ulc - ibuprofène; chlorhydrate de diphénhydramine - capsule - 200mg; 25mg - ibuprofène 200mg; chlorhydrate de diphénhydramine 25mg - other nonsteroidal antiimflammatory agents

Ontilyv Union européenne - français - EMA (European Medicines Agency)

ontilyv

bial portela & companhia s.a. - opicapone - maladie de parkinson - les médicaments anti-parkinsoniens - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

TACTUPUMP FORTE Gel Canada - français - Health Canada

tactupump forte gel

galderma canada inc - adapalène; peroxyde de benzoyle - gel - 0.3%; 2.5% - adapalène 0.3%; peroxyde de benzoyle 2.5% - keratolytic agents

TACTUPUMP Gel Canada - français - Health Canada

tactupump gel

galderma canada inc - adapalène; peroxyde de benzoyle - gel - 0.1%; 2.5% - adapalène 0.1%; peroxyde de benzoyle 2.5% - keratolytic agents

COLD + SINUS DAYTIME COLD + SINUS NIGHTTIME Trousse Canada - français - Health Canada

cold + sinus daytime cold + sinus nighttime trousse

vita health products inc - ibuprofène; chlorhydrate de pseudoéphédrine; ibuprofène; chlorhydrate de pseudoéphédrine; maléate de chlorphéniramine - trousse - 200mg; 30mg; 200mg; 30mg; 2mg - ibuprofène 200mg; chlorhydrate de pseudoéphédrine 30mg; ibuprofène 200mg; chlorhydrate de pseudoéphédrine 30mg; maléate de chlorphéniramine 2mg - other nonsteroidal antiimflammatory agents

SANDOZ ADAPALENE / BENZOYL PEROXIDE Gel Canada - français - Health Canada

sandoz adapalene / benzoyl peroxide gel

sandoz canada incorporated - adapalène; peroxyde de benzoyle - gel - 0.1%; 2.5% - adapalène 0.1%; peroxyde de benzoyle 2.5% - keratolytic agents

TARO-ADAPALENE/BENZOYL PEROXIDE Gel Canada - français - Health Canada

taro-adapalene/benzoyl peroxide gel

taro pharmaceuticals inc - adapalène; peroxyde de benzoyle - gel - 0.1%; 2.5% - adapalène 0.1%; peroxyde de benzoyle 2.5% - keratolytic agents

SANDOZ ADAPALENE / BENZOYL PEROXIDE FORTE Gel Canada - français - Health Canada

sandoz adapalene / benzoyl peroxide forte gel

sandoz canada incorporated - adapalène; peroxyde de benzoyle - gel - 0.3%; 2.5% - adapalène 0.3%; peroxyde de benzoyle 2.5% - keratolytic agents

Opdivo Union européenne - français - EMA (European Medicines Agency)

opdivo

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - agents antinéoplasiques - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.